These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 10095425)

  • 1. [Genetic instability in osteoblastic tumors of the skeletal system].
    Roessner A; Radig K; Schneider-Stock R; Mittler U; Neumann HW
    Verh Dtsch Ges Pathol; 1998; 82():133-43. PubMed ID: 10095425
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic instability in osteoblastic tumors of the skeletal system.
    Radig K; Schneider-Stock R; Mittler U; Neumann HW; Roessner A
    Pathol Res Pract; 1998; 194(10):669-77. PubMed ID: 9820862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular analysis of p53, MDM2, and H-ras genes in osteosarcoma and malignant fibrous histiocytoma of bone in patients older than 40 years.
    Kawaguchi K; Oda Y; Sakamoto A; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
    Mod Pathol; 2002 Aug; 15(8):878-88. PubMed ID: 12181274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Alterations of MDM2 and p53 genes in bone tumors].
    Zhou X; Gao L; Zhe X
    Zhonghua Bing Li Xue Za Zhi; 1997 Oct; 26(5):270-2. PubMed ID: 10374333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Amplification of the CDK4 gene in sarcomas: tumor specificity and relationship with the RB gene mutation.
    Kanoe H; Nakayama T; Murakami H; Hosaka T; Yamamoto H; Nakashima Y; Tsuboyama T; Nakamura T; Sasaki MS; Toguchida J
    Anticancer Res; 1998; 18(4A):2317-21. PubMed ID: 9703873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations of the p53, Rb and MDM2 genes in osteosarcoma.
    Miller CW; Aslo A; Won A; Tan M; Lampkin B; Koeffler HP
    J Cancer Res Clin Oncol; 1996; 122(9):559-65. PubMed ID: 8781571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Status of the p53, Rb and MDM2 genes in canine osteosarcoma.
    Mendoza S; Konishi T; Dernell WS; Withrow SJ; Miller CW
    Anticancer Res; 1998; 18(6A):4449-53. PubMed ID: 9891508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteosarcoma in blood relatives.
    Longhi A; Benassi MS; Molendini L; Macchiagodena M; Picci P; Bacci G
    Oncol Rep; 2001; 8(1):131-6. PubMed ID: 11115584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple genetic alterations in hamster pancreatic ductal adenocarcinomas.
    Chang KW; Laconi S; Mangold KA; Hubchak S; Scarpelli DG
    Cancer Res; 1995 Jun; 55(12):2560-8. PubMed ID: 7780969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of the K-ras and p53 pathways in X-ray-induced lung tumors in the rat.
    Belinsky SA; Middleton SK; Picksley SM; Hahn FF; Nikula KJ
    Radiat Res; 1996 Apr; 145(4):449-56. PubMed ID: 8600505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p53 mutation and absence of mdm2 amplification and Ki-ras mutation in 4-hydroxyamino quinoline 1-oxide induced transplantable osteosarcomas in rats.
    Kido A; Tsujiuchi T; Tsutsumi M; Takahama M; Okajima E; Kobitsu K; Miyauchi Y; Mii Y; Tamai S; Konishi Y
    Cancer Lett; 1997 Jan; 112(1):5-10. PubMed ID: 9029163
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of retinoblastoma susceptible gene accompanied by c-myc amplification in human bone and soft tissue tumors.
    Ozaki T; Ikeda S; Kawai A; Inoue H; Oda T
    Cell Mol Biol (Noisy-le-grand); 1993 Mar; 39(2):235-42. PubMed ID: 8513277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate.
    Lonardo F; Ueda T; Huvos AG; Healey J; Ladanyi M
    Cancer; 1997 Apr; 79(8):1541-7. PubMed ID: 9118036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
    Nielsen GP; Burns KL; Rosenberg AE; Louis DN
    Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 and ras mutations in Ewing's sarcoma.
    Radig K; Schneider-Stock R; Röse I; Mittler U; Oda Y; Roessner A
    Pathol Res Pract; 1998; 194(3):157-62. PubMed ID: 9587933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
    Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
    Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Osteogenic tumors of bone.
    Green JT; Mills AM
    Semin Diagn Pathol; 2014 Jan; 31(1):21-9. PubMed ID: 24680179
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Classical osteoblastoma, atypical osteoblastoma, and osteosarcoma: a comparative study based on clinical, histological, and biological parameters.
    Oliveira CR; Mendonça BB; Camargo OP; Pinto EM; Nascimento SA; Latorre Mdo R; Zerbini MC
    Clinics (Sao Paulo); 2007 Apr; 62(2):167-74. PubMed ID: 17505702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion.
    Saba KH; Cornmark L; Rissler M; Fioretos T; Åström K; Haglund F; Rosenberg AE; Brosjö O; Nord KH
    Genes Chromosomes Cancer; 2019 Oct; 58(10):731-736. PubMed ID: 31066955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What's new in bone forming tumours of the skeleton?
    Franceschini N; Lam SW; Cleton-Jansen AM; Bovée JVMG
    Virchows Arch; 2020 Jan; 476(1):147-157. PubMed ID: 31741049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.